Special Issue "Novel Therapeutic and Drug Delivery Strategies for Neurodegenerative Diseases"

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".

Deadline for manuscript submissions: 31 December 2023 | Viewed by 292

Special Issue Editor

Center for Drug Design, University of Minnesota, Minneapolis, MN 55455, USA
Interests: drug design; medicinal chemistry; neurodegenerative disorders

Special Issue Information

Dear Colleagues,

The multifactorial nature of neurodegenerative disorders and the limited availability of options as true disease-modifying therapies warrant the identification of novel therapeutic strategies against these diseases. The future of successful therapeutic intervention relies on effective drug development and delivery strategies for carefully investigated disease targets. Multipronged approaches targeting multiple disease targets have also offered promising therapeutic outcomes. A significant impediment to developing effective treatment strategies is posed by the limited permeability of effective molecules across the blood–brain barrier. Advances in the field of CNS drug delivery methods have offered promising results in recent years, and provide hope for successful clinical translation. Such basic and translational research endeavors aiming to gain a deeper understanding of disease pathogenesis, and attempting effective engagement of these mechanisms to delay disease onset or progression could result in much-needed breakthroughs. For this Special Issue, we invite research contributions and review articles in the field of neurodegenerative disorders that describe the identification of novel targets, strategies for target engagement, novel approaches for the effective delivery of therapeutics to the brain, and the development of novel formulations. This summary of research discoveries could serve as a valuable resource for future therapeutic development efforts in the field of neurodegenerative disorders.

Dr. Swati S. More
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • drug design
  • drug discovery
  • drug repurposing
  • brain delivery
  • drug carrier
  • drug formulation
  • novel target identification

Published Papers

This special issue is now open for submission.
Back to TopTop